期刊文献+

HPV16L1抗原表达肿瘤模型的建立

CONSTRUCTION OF HPV TYPE 16 L1 ANTIGEN EXPRESSING TUMOR MODEL
下载PDF
导出
摘要 应用基因重组技术,构建pcDNA-L1真核表达载体,经限制性内切酶和序列分析,用脂质体转染技术将其转入B16细胞,G418稳定筛选后IFA法检测其表达,RT-PCR法检测HPV16L1 mRNA 的生成,并将转染细胞接种小鼠皮下,观察成瘤情况及RT-PCR法检测HPv16L1 mRNA的生成。结果,酶切鉴定证实重组质粒中插入的目的基因片段及载体大小、方向和插入位点均正确,在转染的 B16细胞中可见绿色荧光并检测到HPV16L1 mRNA的生成,接种的转染细胞在小鼠皮下可成瘤, 接种后1月在肿瘤组织中可检测到HPV16L1 mRNA的生成,B16细胞转染L1后其致瘤性与转染空载体组和野生型B16细胞组无明显差异。 Recombinant expression vector was constructed by techniques of gene recombination,and identified by restriction endonuclease and sequence analysis. Then the recombinant was transfected into B16 cell by techniques of gene transfection and expressions were detected by RT-PCR and IFA. After that,transfected cells were inoculated into subcutaneous of mouse and the forming tumor and expression of HPV16L1 protein after tumor was formed was observed. Identification of pcDNA- HPV16L1 by enzyme digestion showed that the length,inserted location and direction of the target gene which was inserted into the recombinant was correct and the ex- pression of L1 in transfected cell was observed by IFA. The inoculated cells could form tumor in vivo obviously and HPV16 L1 protein could express in the cells stably.
出处 《分子细胞生物学报》 CSCD 北大核心 2006年第1期9-14,共6页 Journal of Molecular Cell Biology
基金 "十五"国家科技攻关计划(项目编号:2001BA70113)江苏省自然科学基金(项目编号:BK2004057)。
关键词 HPV16 L1 基因转染 肿瘤模型 Human papillomavirus. Expression vector. Gene transfection
  • 相关文献

参考文献12

  • 1Chan, S. H., H. U. Bernard, M. Ratterree, T. A. Birkebak, A. J. Faras & R.Ostrow, 1997, Genomic diversity and evolution of papillomaviruses in rhesus monkeys. J.Virol. 71 : 4938-4943.
  • 2De Villiers,E.M., 2001, Taxonomic classification of papillomaviruses. Papillomavirus Rep., 12: 57-63.
  • 3Munoz,N., F.X. Bosch, S .De Sanjose, L. Tafur, L Izarzugaza & M. Gill , 1992, The causal link between human papillomavirus and invasive cervical cancer: A populationbased case-control study in Colombia and Spain. lnt.J.Cancer 52: 743-749.
  • 4Bosch,F.X., A. Lorincz, N. Munoz, C.J. Meijer & K.V.Shah, 2002, The causal relation between human papillo-mavirus and cervical cancer. J.Clin. Pathol., 55: 244-265.
  • 5Walboomers,J.M., M.V. Jacobs, M.M. Manos, F.X. Bosch,J.A. Kummer, K.V. Shah, Pj. Snijders, J. Peto, Cj.Meijer & N. Munoz, 1999, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J.Pathol., 189: 12-19.
  • 6Sehiffman,M.H., H.M. Bauer, R.N. Hoover, A.G. Glass,D.M. Cadell, B.B. Rush, D.R. Scott, M.E. Sherman, R.J. Kurman & S. Waeholder, 1993, Epidemiologie evidence showing that human papillomavirus infection causesmost cervical intraepithelial . neoplasiaJ. Natl Cancer Inst.,85: 958-964.
  • 7Kjaer,S. K., A. J. C.van den Brule, J. E. Bock, P. A. Poll,G. Engholm, M. E. Sherman, J. M. M. Walboomers & C.J. L. M. Meijer, 1996, Human papillomavirus-the most significant risk determinant of cervical intraepithelial neoplasia., Int. J. Cancer, 65: 601-606.
  • 8高慧,黄正芳,徐向明,孙强,殷俊,杨玲,贾筱琴,朱洪,李厚达.扬州地方株HPV16L1基因的克隆及序列分析[J].东南大学学报(医学版),2005,24(1):17-20. 被引量:5
  • 9Kirbauer,R, F Booy, N Cheng, D.R. Lowy & J.T. Schiller,1992, PapiUomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.Proc.Natl.A c ad.Sc i. USA , 89:12180-12184.
  • 10Wu,T. C., F. G. Guamieri, K. F. Staveley-O'Carroll, R.P. Viscidi, H. I. Levitsky, L. Hedrick, K. R. Cho, J. T.August & D. M. Pardoll. 1995. Engineering an paintracellular thway for major histocompatibility complex class Ⅱ presentation of antigens. Proc. Natl. Acad. Sci. USA, 92:11671.

二级参考文献14

  • 1Devilers. Heterogenity of the human papillomavirus group. J Viral, 1989,63:1 542.
  • 2Meneguzzi G. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology,1991,181:62.
  • 3Pater M. Human papillomavirus type 16 and 18 sequences in carcinoma cell lines of the cervix. Virology, 1985,145:313.
  • 4Wu TC, Guamieri FG, Staveley OCKF, et al. Engineering an intracellular pathway for major histocompatibility complex class Ⅱ presentation of antigens. Proc Nail Acad Sci USA, 1995,92:11671.
  • 5Fehkamp Mariet CW, Smits HL, Michel PM, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tmnor induced by hmnan papillomavirus type 16-transformed cells. Eur J Immunol, 1993,23:2 242.
  • 6Van Tendeloo VF,Ponsaerts P,Van Broeekhoven C,et al. Efficient generation of stably electrotransfected human hematopoietic cell lines without drug selection by consecutive FAC sorting. J Cytometry, 2000,41 : 304.
  • 7ICENOGLE J P,SATHYA P,MILLER D L,et al. Nucleotide and amino acid sequence variation in the L1 and E7 open reading frames of human papillomavirus type 6 and type 16[J]. Virology,1991,184:101-107.
  • 8DAS B C,SHARMA J K,GOPALAKRISHNA V,et al. A Frequency of human papillomavirus DNA sequences incervical carcinomas of Indian women as revealed by southern blot hybridization and poly--merase chain reaction[J]. Med Virol,1992,36:239-245.
  • 9BOSCH F X,MANOS M M,MUNOZ N,et al. Prevalence of human papillomavirus in cervical cancer:a worldwide prospective[J]. Natl Cancer Inst,1995,87:796-802.
  • 10SEEDORF K,KRAEMMER G,DUERST M,et al. Human papillomavirus type 16 DNA sequence[J]. Virol,1985,145:181-185.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部